Work

Widening the therapeutic window: How tumor irradiation harnesses dendritic cells to locally amplify CAR T cells in solid tumor

Year: 2026

Type: article

Abstract: Much effort has been devoted to making chimeric antigen receptor (CAR) T cell therapy as effective in solid tumors as it has become in B cell malignancies. Although clinical trials have demonstrated that doses up to 5 × 108 CAR T cells are generally safe, these doses rarely produce durable persistence.1,2,3,4 Mesothelin- and EGFRvIII-directed CAR T cells become undetectable within weeks to months after infusion,1,2 while GD2-and HER2-directed CAR T cells persist at levels below those required to sustain effector-to-target (E:T) ratios for enduring tumor control.

Source: Molecular Therapy Oncology

DOI: 10.1016/j.omton.2026.201317

Authors: Sophia Navarre, Jalal Ahmed

Institution: Icahn School of Medicine at Mount Sinai

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,900